{
  "abstract": "Background: Combined COVID-19 and influenza vaccines may increase protection against respiratory disease, notably by improving COVID-19 uptake, which lags behind influenza coverage globally. Data on the effectiveness of mRNA-1083 against both diseases are promising. We evaluate the health impact of introducing mRNA-1083 into the Dutch vaccination program versus separate administration of standard-dose influenza and current COVID-19 vaccines.\n\nMethods: A static decision tree model evaluated the health impact of annual mRNA-1083 vaccination. The target population included adults ≥60 years and high-risk individuals ≥50 years. Vaccine effectiveness was derived from clinical trial data and a meta-analysis; coverage followed Dutch influenza vaccination levels. Incidence was derived from primary care surveillance (respiratory season 2023/24). Hospitalizations and in-hospital mortality were obtained from national ICD-10-coded hospital records (2023). Nursing home mortality was informed by a Dutch study on deaths associated with LRTI, ILI, and COVID-19. Outcomes were expressed as averted cases per category.\n\nResults: Incorporating mRNA-1083 substantially reduces disease burden versus the current strategy. For COVID-19, this corresponds to 13,331 (10,527 - 15,693) GP visits, 4,194 (3,541 - 4,698) hospitalizations, and 1,297 (1,104 - 1,445) deaths averted in a full year. The higher effectiveness of the influenza component in the combined vaccine further prevents a total of 12,222 (-1,203 - 22,103) GP visits, 3,372 (242 - 6,285) cardiorespiratory hospitalizations, and 1,194 (457 - 1,851) deaths in the base-case scenario.\n\nConclusions: mRNA-1083 for older adults and high-risk groups could substantially reduce disease burden due to respiratory infections in the Netherlands. These findings support the value of combination vaccines for mitigating seasonal respiratory disease.\n\nKey messages: • The use of a combined COVID‑19–influenza mRNA vaccine is projected to substantially reduce the burden of seasonal respiratory disease.\n\n• mRNA‑1083 could avert ∼25,500 GP visits, ∼7,600 hospitalisations, and ∼2,500 deaths from COVID‑19 and influenza among older and high‑risk adults in the Netherlands.",
  "abstract_shown": true,
  "affiliations": [],
  "article_type": "abstract",
  "arxiv": null,
  "author_total": 7,
  "authors": [
    {
      "name": "SL De Braak"
    },
    {
      "name": "J Luttjeboer"
    },
    {
      "name": "TA Westra"
    },
    {
      "name": "VJ Lempers"
    },
    {
      "name": "MJ Postma"
    },
    {
      "name": "C Boersma"
    },
    {
      "name": "S Van der Pol"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/5gwzhs1p648nq.bib",
  "cited_by": 0,
  "doi": "10.1093/eurpub/ckag169.630",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13697949/",
  "id": "5gwzhs1p648nq",
  "issns": [
    "1101-1262",
    "1464-360X"
  ],
  "landing_url": "https://doi.org/10.1093/eurpub/ckag169.630",
  "language": "en",
  "licence": "CC-BY-NC-4.0",
  "licence_label": "CC BY-NC 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "3. PARALLEL PROGRAMME"
    ],
    [
      "heading",
      "AcademicSubjects/MED00860"
    ],
    [
      "heading",
      "AcademicSubjects/SOC01210"
    ],
    [
      "heading",
      "AcademicSubjects/SOC02610"
    ],
    [
      "openalex",
      "2713|Influenza Virus Research Studies"
    ]
  ],
  "openalex": "W7223702544",
  "pdf_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13697949/pdf/?tool=EBI",
  "pmcid": "PMC13697949",
  "pmid": null,
  "published": "2026-10-01",
  "publisher": "Oxford University Press",
  "ris": "https://research.draconitic.com/paper/5gwzhs1p648nq.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:18:55Z",
      "native_id": "PMC13697949",
      "source": "pmc",
      "url": "https://doi.org/10.1093/eurpub/ckag169.630"
    },
    {
      "first_seen": "2026-10-30T12:21:31Z",
      "native_id": "PMC:PMC13697949",
      "source": "europepmc",
      "url": "https://europepmc.org/article/PMC/PMC13697949"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2713|Influenza Virus Research Studies",
      "subfield": "epidemiology-public-health"
    }
  ],
  "title": "Health impact of a combined COVID-19-influenza mRNA vaccine in older and high-risk Dutch adults",
  "title_text": "Health impact of a combined COVID-19-influenza mRNA vaccine in older and high-risk Dutch adults",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:34:54Z",
  "url": "https://research.draconitic.com/paper/5gwzhs1p648nq",
  "venue": "The European Journal of Public Health",
  "versions": []
}